Literature DB >> 18097514

Individualized prostate biopsy strategy for Chinese patients with different prostate-specific antigen levels.

Bo Dai1, Ding-Wei Ye, Yun-Yi Kong, Yi-Jin Shen, Bo-Hua Wang.   

Abstract

AIM: To evaluate the best individualized prostate biopsy strategies for Chinese patients with suspected prostate cancer.
METHODS: The present study included 221 Chinese patients who underwent transrectal ultrasound guided prostate biopsies for the first time. All patients underwent the same 10-core biopsy protocol. In addition to the Hodge sextant technique, four more biopsies were obtained from the base and middle regions of bilateral peripheral zones. The differences between 10-core and sextant strategies in cancer detection among patients with different prostate specific antigen (PSA) levels were evaluated. The relationship between PSA level, number of positive biopsy cores and organ-confined cancer rate in prostate cancer patients was also analyzed.
RESULTS: The overall prostate cancer detection rate was 40.7% in the 221 patients. The 10-core strategy increased cancer detection by 6.67% (6/90) in our patients (P < 0.05). The increased cancer detection rates decreased significantly when the patient PSA level increased from 0-20 ng/mL to 20.1-50 ng/mL and > 50 ng/mL (P < 0.01). The number of positive biopsy cores in prostate cancer patients increased significantly with increasing patient PSA level (P < 0.01). The rate of organ-confined prostate cancer decreased significantly with increasing patient PSA level (P < 0.01).
CONCLUSION: The extended 10-core strategy is recommended for Chinese patients with PSA = or < 20 ng/mL and the sextant strategy is recommended for those with PSA > 50 ng/mL. For patients with PSA ranging from 20.1 ng/mL to 50 ng/mL, the 10-core strategy should be applied in patients with life expectancy = or > 10 years and the sextant strategy should be applied in those with life expectancy < 10 years.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18097514     DOI: 10.1111/j.1745-7262.2008.00345.x

Source DB:  PubMed          Journal:  Asian J Androl        ISSN: 1008-682X            Impact factor:   3.285


  13 in total

Review 1.  The results of transperineal versus transrectal prostate biopsy: a systematic review and meta-analysis.

Authors:  Peng-Fei Shen; Yu-Chun Zhu; Wu-Ran Wei; Yong-Zhong Li; Jie Yang; Yu-Tao Li; Ding-Ming Li; Jia Wang; Hao Zeng
Journal:  Asian J Androl       Date:  2011-11-21       Impact factor: 3.285

Review 2.  Recent advances in bone-targeted therapies of metastatic prostate cancer.

Authors:  Xiyun Deng; Guangchun He; Junwen Liu; Feijun Luo; Xiaoning Peng; Shigang Tang; Zhiyong Gao; Qinlu Lin; Jill M Keller; Tao Yang; Evan T Keller
Journal:  Cancer Treat Rev       Date:  2014-04-16       Impact factor: 12.111

3.  Anti-tumor activity of curcumin against androgen-independent prostate cancer cells via inhibition of NF-κB and AP-1 pathway in vitro.

Authors:  Shuanglin Liu; Zhihua Wang; Zhiquan Hu; Xing Zeng; Youyuan Li; Yaowu Su; Chuanhua Zhang; Zhangqun Ye
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-08-07

4.  Prognostic factors in Chinese patients with metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy.

Authors:  Yuan-Yuan Qu; Bo Dai; Yun-Yi Kong; Ding-Wei Ye; Xu-Dong Yao; Shi-Lin Zhang; Hai-Liang Zhang; Chun-Guang Ma; Wei-Yi Yang
Journal:  Asian J Androl       Date:  2012-11-12       Impact factor: 3.285

5.  Retrospective descriptive analysis of the physiological kinetics of prostate-specific antigen in men older than 75 years.

Authors:  Maria Chiara Sighinolfi; Salvatore Micali; Stefano De Stefani; Arrigo Cicero; Filippo Cianci; Marco Giacometti; Giampaolo Bianchi
Journal:  Asian J Androl       Date:  2009-05-18       Impact factor: 3.285

6.  Prostate-specific antigen half-life: a new predictor of progression-free survival and overall survival in Chinese prostate cancer patients.

Authors:  Guo-Wen Lin; Xu-Dong Yao; Shi-Lin Zhang; Bo Dai; Chun-Guang Ma; Hai-Liang Zhang; Yi-Jun Shen; Yao Zhu; Yi-Ping Zhu; Guo-Hai Shi; Xiao-Jian Qin; Ding-Wei Ye
Journal:  Asian J Androl       Date:  2009-02-02       Impact factor: 3.285

Review 7.  Prostate cancer in Asian men.

Authors:  Kazuto Ito
Journal:  Nat Rev Urol       Date:  2014-03-04       Impact factor: 14.432

8.  Docetaxel with or without zoledronic acid for castration-resistant prostate cancer.

Authors:  Yue Pan; Haiyong Jin; Wei Chen; Zhixian Yu; Tingyu Ye; Yuancai Zheng; Zhiliang Weng; Feng Wang
Journal:  Int Urol Nephrol       Date:  2014-09-16       Impact factor: 2.370

9.  miR-205 is frequently downregulated in prostate cancer and acts as a tumor suppressor by inhibiting tumor growth.

Authors:  Ning Wang; Qi Li; Ning-Han Feng; Gong Cheng; Zhao-Long Guan; Yang Wang; Chao Qin; Chang-Jun Yin; Li-Xin Hua
Journal:  Asian J Androl       Date:  2013-08-26       Impact factor: 3.285

10.  Serum early prostate cancer antigen (EPCA) level and its association with disease progression in prostate cancer in a Chinese population.

Authors:  Zhigang Zhao; Wenjing Ma; Guohua Zeng; Defeng Qi; Lili Ou; Yeping Liang
Journal:  PLoS One       Date:  2011-05-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.